Back to search

Boston University

The potential of using stem cell therapy to treat type 1 diabetes

Abstract

dc:description.abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic beta cells, resulting in lifelong dependence on exogenous insulin and ongoing risk of complications despite modern therapy. Stem-cell-based therapies have emerged as an alternative strategy for beta-cell replacement, offering some advantages when compared to whole organ pancreas and cadaveric islet therapies which are limited by donor scarcity and require immunosuppression to avoid rejection of the therapy. This study reviews the use of mesenchymal stem cells (MSCs), which act through immunomodulation and cytoprotective signaling that support residual islets, and human pluripotent stem-cell-derived islets (SC-islets) which provide a renewable source of insulin-secreting cells. Early studies of human embryonic stem cell (hESC)-derived pancreatic endoderm, autologous chemically induced pluripotent stem cell (CiPSC)-derived islets, and the allogeneic Zimislecel product demonstrate that SC-islets can restore endogenous insulin secretion, improve glycemic control, and in many cases achieve insulin independence under immunosuppression. However, these islets show partial immaturity, off-target endocrine populations, and are susceptible to immune attack. Encapsulation devices, gene-edited hypo immune islets, and localized immune modulation are being developed to reduce or eliminate systemic immunosuppression. Current data indicate that stem-cell-based strategies have progressed to clinically credible beta-cell replacement platforms that, with further improvements in cell quality, immune protection, and delivery, could become widely used disease-modifying therapies for T1D. However, it has been demonstrated that SC-beta graft cells can work, but not without avoiding the limitation of immunosuppression. By focusing on utilizing gene edited hypo immune cells, I believe we can manufacture SC-islets on a large scale while eliminating or reducing the need for chronic immunosuppression to make SC-islet therapy a sustainable and widespread T1D treatment.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Brady, Alyson
Advisors dc:contributor.advisor
  • Tornheim, Keith
  • Bottenfield, Karen
ORCID dc:identifier.orcid

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/52972

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Brady, Alyson. The potential of using stem cell therapy to treat type 1 diabetes. masters thesis, Boston University, 2026. https://hdl.handle.net/2144/52972